Metropolis Healthcare Limited has informed the Exchange regarding a press release dated November 04, 2025, titled " Metropolis Healthcare maintains Growth Momentum; Revenue Rises 23% YoY to ₹429 Crore, EBITDA grows by 19%. ".
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare reported Q2FY26 (quarter ended September 30, 2025) consolidated revenue of ₹429 crore, up 23% year-on-year, with EBITDA growing 19% YoY. Patient volumes rose 11% and test volumes 12% YoY, while revenue per patient and revenue per test both grew in double digits (11% and 10%). The B2B segment outpaced B2C with 33% revenue growth versus 16%. High-value portfolios — TruHealth wellness (~24%) and Specialty (~33%) — drove much of the momentum. The company highlighted that Core Diagnostics, acquired recently, turned PAT-positive within two quarters. North India's revenue contribution rose to 19% and Tier III city revenues grew 13%. The Board declared a 200% dividend (₹4 per share).
Strong, broad-based quarterly performance with double-digit growth across volumes, pricing, and segments is positive for the stock. The dividend declaration signals cash-flow confidence, though the company noted softer seasonal demand due to lower vector-borne disease incidence, which may temper near-term enthusiasm.